RLMD
Relmada Therapeutics, Inc. NASDAQ Listed Jun 20, 2014$6.50
After hrs
$6.51
+0.00%
Mkt Cap $477.0M
52w Low $0.52
80.0% of range
52w High $8.00
50d MA $7.00
200d MA $4.66
P/E (TTM)
—
EV/EBITDA
—
P/B
3.0x
Debt/Equity
0.0x
ROE
-66.3%
P/FCF
-5.8x
RSI (14)
56.90
ATR (14)
$0.41
Beta
0.45
50d MA
$7.00
200d MA
$4.66
Avg Volume
1.3M
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
CIK (SEC)
Phone
786 629 1376
2222 Ponce de Leon Boulevard · Coral Gables, FL 33134 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.14 | -0.27 | -92.9% | 6.25 | +4.0% | -2.9% | -3.5% | +4.1% | +9.2% | -2.0% | — |
| Nov 13, 2025 | AMC | -0.04 | -0.30 | -650.0% | 3.88 | -8.8% | +1.8% | +0.5% | +7.6% | -2.1% | +3.3% | — |
| Aug 7, 2025 | AMC | -0.25 | -0.30 | -20.0% | 0.60 | -1.1% | -2.4% | -4.1% | +4.4% | -3.4% | +6.9% | — |
| May 12, 2025 | AMC | -0.31 | -0.58 | -87.1% | 0.40 | -3.0% | -2.1% | +10.3% | -3.9% | +11.5% | +10.4% | — |
| Mar 27, 2025 | AMC | -0.70 | -0.62 | +11.4% | 0.30 | +4.5% | -0.4% | -9.0% | +1.3% | +10.8% | -9.0% | — |
| Nov 7, 2024 | AMC | -0.65 | -0.72 | -10.8% | 0.81 | -0.3% | +0.6% | -0.9% | +1.5% | -2.7% | -1.6% | — |
| Aug 7, 2024 | AMC | -0.83 | -0.59 | +28.9% | 0.81 | -0.9% | -29.0% | +0.0% | +0.0% | +10.4% | +1.2% | — |
| May 8, 2024 | AMC | -0.90 | -0.72 | +20.0% | 0.96 | +1.8% | -0.8% | -7.1% | +0.0% | +3.1% | -4.4% | — |
| Mar 19, 2024 | AMC | -0.88 | -0.84 | +4.5% | 1.34 | +3.0% | -17.2% | +5.4% | +4.3% | +0.8% | -4.9% | — |
| Nov 8, 2023 | AMC | -0.95 | -0.73 | +23.2% | 0.75 | +0.3% | -0.3% | -3.0% | -2.8% | +4.6% | +2.7% | — |
| Aug 8, 2023 | AMC | -0.92 | -0.84 | +8.7% | 0.64 | +0.4% | +7.1% | +5.1% | +8.4% | +2.6% | +7.2% | — |
| May 11, 2023 | AMC | -0.88 | -0.87 | +1.1% | 0.79 | -2.2% | -6.3% | +4.0% | -5.5% | +6.2% | +0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 18 | H.C. Wainwright | Initiates | Buy | $12 | $6.60 | $6.74 | +2.1% | +2.0% | +2.4% | -1.7% | — | — |
| Mar 20 | Mizuho | Maintains | Outperform → Outperform | — | $6.25 | $6.50 | +4.0% | -2.9% | -3.5% | +4.1% | +9.2% | -2.0% |
| Jan 23 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $3.96 | $4.31 | +8.8% | -1.5% | +1.8% | +3.3% | -3.7% | -1.0% |
| Nov 19 | Mizuho | Upgrade | Neutral → Outperform | — | $4.27 | $4.50 | +5.4% | -2.1% | +3.3% | -1.2% | +0.7% | -0.9% |
| Dec 5 | Mizuho | Downgrade | Outperform → Neutral | — | $0.63 | $0.64 | +1.6% | -28.6% | +1.7% | +5.1% | -2.3% | -11.1% |
| Dec 4 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $0.69 | $0.69 | +0.4% | -9.0% | -28.6% | +1.7% | +5.1% | -2.3% |
| Jun 5 | Goldman Sachs | Downgrade | Neutral → Sell | — | $0.74 | $0.72 | -2.7% | +0.3% | +2.7% | -3.0% | +5.8% | -2.6% |
| Jun 15 | Mizuho | Maintains | Buy → Buy | — | $0.64 | $0.64 | +0.0% | -0.8% | +2.0% | +10.0% | -4.5% | -6.2% |
| Jan 23 | SVB Leerink | Maintains | Outperform → Outperform | — | $1.19 | $1.18 | -0.8% | -6.7% | -4.5% | +3.8% | -4.5% | -1.9% |
| Oct 14 | Guggenheim | Downgrade | Buy → Neutral | — | $1.62 | $1.57 | -3.1% | -4.3% | +9.7% | +11.8% | -2.6% | +3.8% |
| Oct 14 | Goldman Sachs | Downgrade | Buy → Neutral | — | $1.62 | $1.57 | -3.1% | -4.3% | +9.7% | +11.8% | -2.6% | +3.8% |
| Oct 13 | Oppenheimer | Downgrade | Outperform → Perform | — | $6.34 | $1.67 | -73.7% | -74.4% | -4.3% | +9.7% | +11.8% | -2.6% |
| Sep 23 | Goldman Sachs | Maintains | Buy → Buy | — | $6.11 | $5.99 | -2.0% | +4.4% | -0.3% | +4.6% | +4.5% | +4.2% |
| Sep 6 | Guggenheim | Maintains | Buy → Buy | — | $5.94 | $6.04 | +1.7% | +4.0% | -2.1% | +5.8% | -0.3% | +1.1% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.25 | $4.13 | -2.8% | -5.9% | -1.0% | -6.1% | -0.5% | +7.0% |
| Mar 24 | Goldman Sachs | Maintains | Buy → Buy | — | $4.67 | $4.68 | +0.2% | +7.5% | +2.6% | +0.0% | +0.0% | +1.2% |
| Dec 20 | SVB Leerink | Maintains | Outperform → Outperform | — | $3.81 | $3.80 | -0.3% | +7.9% | +1.9% | +0.7% | +5.5% | -2.2% |
| Nov 18 | Mizuho | Maintains | Buy → Buy | — | $4.29 | $4.52 | +5.4% | -1.9% | -3.1% | -4.9% | -2.1% | +2.9% |
| Nov 25 | Goldman Sachs | Maintains | Buy → Buy | — | $6.98 | $6.96 | -0.3% | +0.0% | +3.2% | -1.2% | -1.8% | -1.7% |
| Nov 25 | Jefferies | Maintains | Buy → Buy | — | $6.98 | $6.96 | -0.3% | +0.0% | +3.2% | -1.2% | -1.8% | -1.7% |
| Nov 25 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $6.98 | $6.96 | -0.3% | +0.0% | +3.2% | -1.2% | -1.8% | -1.7% |
| Oct 28 | Goldman Sachs | Downgrade | Buy → Neutral | — | $6.61 | $6.16 | -6.8% | -4.2% | -1.6% | -0.6% | -3.4% | +5.2% |
| May 4 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $7.88 | $8.50 | +7.9% | +2.0% | +4.0% | -1.9% | -1.2% | +2.1% |
| Apr 21 | Goldman Sachs | Maintains | Buy → Buy | — | $7.08 | $7.32 | +3.4% | -5.9% | +4.7% | +0.6% | +2.9% | +4.4% |
| Jan 27 | Jefferies | Maintains | Buy → Buy | — | $8.66 | $8.41 | -2.9% | +2.9% | +5.4% | -1.6% | +1.4% | -5.3% |
| Dec 16 | Guggenheim | Maintains | Buy → Buy | — | $6.83 | $8.01 | +17.3% | +17.1% | +4.9% | +3.3% | +0.2% | -1.2% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Trellis Research Limited (RLMD) disclosed material non-public information under Regulation FD, suggesting a significant company development or guidance update that could immediately impact stock valuation and trading activity.
Mar 20
8-K · 8.01
!! High
Relmada Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Relmada's NDV-01 achieved a 76% complete response rate in Phase 2 bladder cancer trials at 12 months, with favorable safety, supporting advancement toward potential commercialization.
Mar 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 11,063,862 | $77M | New | Mar 2026 |
| 2 | Marshall Wace, Llp | 4,481,606 | $31M | Added | Mar 2026 |
| 3 | Millennium Management | 3,907,265 | $27M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 3,076,570 | $21M | New | Mar 2026 |
| 5 | Braidwell Lp | 1,582,257 | $8M | New | Dec 2025 |
| 6 | Susquehanna International Group, Llp | 1,011,572 | $7M | Added | Mar 2026 |
| 7 | Soleus Capital Management, L.p. | 842,106 | $6M | New | Mar 2026 |
| 8 | Acadian Asset Management Llc | 712,540 | $5M | Added | Mar 2026 |
| 9 | Qube Research & Technologies Ltd | 653,333 | $5M | Added | Mar 2026 |
| 10 | Opaleye Management Inc. | 935,000 | $5M | New | Dec 2025 |
| 11 | Stempoint Capital Lp | 597,409 | $4M | New | Mar 2026 |
| 12 | Point72 Asset Management | 504,820 | $4M | Added | Mar 2026 |
| 13 | Adar1 Capital Management, Llc | 451,918 | $3M | New | Mar 2026 |
| 14 | Knott David M Jr | 439,300 | $3M | New | Mar 2026 |
| 15 | Woodline Partners Lp | 421,052 | $3M | New | Mar 2026 |
| 16 | Two Sigma Investments, Lp | 408,095 | $3M | Reduced | Mar 2026 |
| 17 | Jones Hill Capital Lp | 342,752 | $2M | New | Mar 2026 |
| 18 | Rbf Capital, Llc | 240,000 | $2M | Reduced | Mar 2026 |
| 19 | Ally Bridge Group (Ny) Llc | 210,525 | $1M | New | Mar 2026 |
| 20 | Jane Street Group, Llc | 271,109 | $1M | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 9
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | AdvisorShares Psychedelics ETF | 295,872 | $2M | Mar 2026 |
| 2 | Fidelity Extended Market Index Fund | 331,844 | $2M | Feb 2026 |
| 3 | Fidelity Total Market Index Fund | 144,336 | $658K | Feb 2026 |
| 4 | Fidelity Series Total Market Index Fund | 116,051 | $529K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 45,197 | $206K | Feb 2026 |
| 6 | Schwab Total Stock Market Index Fund | 53,081 | $188K | Jan 2026 |
| 7 | Victory Extended Market Index Fund | 6,908 | $25K | Jan 2026 |
| 8 | U.S. SMALL CAP PORTFOLIO | 2,078 | $7K | Jan 2026 |
| 9 | State Street Balanced Index Fund | 620 | $4K | Mar 2026 |
Valuation
Market Cap
$477.0M
Enterprise Value
$174.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.07x
P/B
2.97x
P/S
—
P/FCF
-5.84x
EV/EBITDA
—
Shares Out
39.5M
Financials (TTM)
Revenue
$0
Net Income
-$58.9M
EBITDA
-$58.9M
Free Cash Flow
-$45.8M
Op Cash Flow
-$45.8M
EPS Basic
$-1.45
EPS Diluted
$-1.11
EPS Forward
$-0.76
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$94.0M
Total Liab.
$7.5M
Total Equity
$86.5M
Cash
$93.0M
LT Debt
$0
Book Value/Sh
$2.19
Debt/Equity
0.00x
Current Ratio
14.62
Quick Ratio
14.62
Returns & Growth
ROE
-66.3%
ROA
-61.1%
ROIC
-67.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
+45.3%
Price Returns
2W
-2.8%
1M
-4.1%
3M
+58.1%
6M
+59.9%
12M
+861.3%
Technicals
52W High
$8.00
52W Low
$0.52
50d MA
$7.00
200d MA
$4.66
RSI (14)
56.90
ATR (14)
$0.41
Beta
0.45
Avg Volume
1.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$9.00
High
$10.00
Low
$8.00
Median
$9.00
Data updated apr 26, 2026 11:02pm
· Source: financialmodelingprep.com